The June 2024 quarter marked a period of substantial financial growth and strategic advancements for Melbourne-based pharmaceutical manufacturer IDT. The company's impressive performance can be attributed to its focus on three core pillars: Advanced Therapies, Active Pharmaceutical Ingredient
The introduction of generative artificial intelligence (AI) into the life sciences manufacturing sector heralds a new era of innovation and efficiency. With the life sciences field continuously pushing for faster product launches, increased production capacity, enhanced supply chain security, and
Phlow Corp., a company dedicated to advancing the Richmond region into a hub for pharmaceutical manufacturing, is making significant strides as it raises $25 million from investors. Following the initiation of its medicine ingredients manufacturing operations in Petersburg last year, this
In a recent significant development set to change the healthcare landscape, Germfree and Orgenesis Inc. have joined forces. This strategic partnership establishes a noble ambition: to revolutionize the production of much-needed cell and gene therapies. The aim is clear—to enhance the availability o
In a bold move to expand its immunology portfolio, Johnson & Johnson has announced the acquisition of Proteologix, Inc. for an $850 million upfront payment, with additional milestone payments on the horizon. This strategic purchase positions Johnson & Johnson at the forefront of
As we progress into the 2020s, the pharmaceutical industry is steered toward an era of both exciting potential and challenges. The year 2024 is poised to be pivotal, influenced by a complex mix of factors including rigorous regulation, technological advancements, demand for sustainability, and the
